This is how Bashers work: READ & LEARN! They will do

New Post Public Reply Private Reply Replies (1) Message Board
JAVA1
This is how Bashers work: READ & LEARN!

They will do their best to remain anonymous or use a fake identity.
They will use about 10% fact and 90% suggestion. The carefully chosen and carefully placed facts are there to lend credibility to the rest of what they say, which is merely unfounded suggestion intended to deceive.
To start with, they wait for others to help you learn about whatever stock interests you.
Then they develop rapport and build a support base before initiating their bashing routine.
They will enter the discussion with humor and will reply to everyone else who replies to their target's postings.
A single basher often will use two or more aliases to make it appear that a discussion has begun. He or she will post from multiple ISP's and use multiple "handles."
The basher usually does not start with an all-out slam of the stock. He or she will build up to the bashing over a period of time.
Bashers will identify their foe, usually the board's "guru." Then the clever bashers will use them to their own advantage and lead them, but they will not follow the "guru's" lead.
Bashers only bash until the tide and momentum turns, then they simply let doubt carry their message the rest of the way. Bashers try to give the appearance of being open-minded.
Bashers are bold in their statements, knowing that people like to follow strength. Bashers like to write headlines in capital letters and use catchy phrases.
Bashers will "pour it on" as their position gains momentum. Bashers don't worry about being labeled a "basher," since the current newbie being targeted won't know the basher's history.
When identified, a basher will put up a brief fight, then back off and return in an hour or so. But if a basher's foe is a weak in reasoning powers, the basher will just come on even stronger and push ahead with the bashing.
If a basher is discredited, he or she will change aliases, maybe change the gender of the alias, and continue on that board or another one.
A basher's goal is to limit the momentum of the run, but not to tank the company or create a plunge in the stock; thus a basher will tend to be subtle and consistent.
The basher is out to kill the dreams of profits, but not the company or the stock itself.
Bashers use questions to create critical thinking, but they guide the critical thinking toward their own intended conclusion. What is posted ends up not actually being critical thinking on the part of the investor; it just looks like it is.
The investor feels informed but, in reality, the basher has guided the thinking. Bashers try to look nice. They don't lie, use profanity, or resort to name-calling.
Bashers encourage people to call the company, knowing that 99% of them won't ever do so. Instead, all but the most savvy investors will take the basher's word for claims made.
If an investor does call, a smart basher can always find something that is inaccurate in the report of what the company said.
Bashers also discourage people from taking the company's word for anything, saying, "Of course that is what the company is going to claim."
If the company's history or its PR is negative, a basher will continually return to that point.
The basher will compile a list of anything negative about the company that is true before beginning to bash it.
If the price of the company's stock rises, the basher will attribute that to the hype or the PR, claim it's only a temporary mass reaction, say "it's just the market," or give any reason other than the actual merits of the stock itself.
If other posters share a basher's "concerns", the basher will play on his or her good luck and share even more "concerns."
Bashers always cite low volume, even when it's not true.
A basher who is writing from three or four aliases can dominate a board and wear down the rest of the posters.
Bashers will bait the hypesters into personality debates, diverting their focus and efforts from the stocks to the posters.
Bashers will say they are trying to present the facts from a "different perspective."
Bashers will try to promote other stocks that would-be investors can investigate instead of the one they are bashing.
Bashers refuse to respond to any challenges on the "values" or ethics of what they are doing. For them, it's a game, and they are playing it by their own rules.


Nanotech Entertainment Inc. (NTEK) Stock Research Links

NTEK Board Company Profile Buy Rating Time & Sales News Filings Financials
Here We Go!!!!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 89

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 16

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Quest Diagnostics Faces Class Action After Data Breach

Updated Category News Views 36

Data Breach Rocks Quest Diagnostics October 2026 caught Quest Diagnostics in a bind they wish they could escape—a classic tech breach with personal info hanging out to dry. When a cyber ghost slipped into Quest's Quanum Lab Services Manager, it wasn't to deliver flowers. Nope, this unauthorized access was no friendly visit, forcing Quest to scream foul and play serious...

Continue Reading
Millrose Faces Securities Fraud Suit Amidst Decline

Updated Category News Views 148

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Continue Reading
John Wong's Decade as Estate Planning Specialist

Updated Category News Views 68

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 66

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
SLM Faces Legal Scrutiny as Losses Mount Amid Pause

Updated Category News Views 115

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 210

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 198

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Tony Perkins' Church Tour amid Controversial Vote

Updated Category News Views 89

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Santander to Redeem €187.6 Million CoCos Efficiently

Updated Category News Views 146

Banco Santander Approaches €187.6 Million CoCos Redemption BANCO SANTANDER S.A. has made a significant announcement regarding the redemption of its contingent convertible securities (CoCos). This decision, which is seen as a strategic move, highlights the bank's commitment to financial efficacy and investor satisfaction. Additionally, the redemption covers a total...

Continue Reading
Revolutionizing ADC Characterization with Biozen Native Columns

Updated Category News Views 480

Transforming Biotherapeutic Characterization First of its Kind in Biotherapeutic Antibody Characterization Phenomenex Inc., a leader in separation science technology, has launched Biozen Native RP-1 and RP-5 chromatography columns. These innovative products are engineered to meet the growing demand for effective characterization methods for Antibody-Drug Conjugates...

Continue Reading
TG Therapeutics to Attend the Upcoming Global Healthcare Event

Updated Category News Views 274

Participation in Global Healthcare Conference TG Therapeutics, Inc. (NASDAQ: TGTX) is making waves as it prepares to take part in a prestigious healthcare event. Michael S. Weiss, the Chairman and CEO of the company, is scheduled to speak during the fireside chat at the Goldman Sachs Annual Global Healthcare Conference. This significant event will be hosted in Miami and...

Continue Reading
Ogury One: Revolutionizing Advertising in a Privacy-Centric World

Updated Category News Views 244

Ogury One: A New Era in Digital Advertising Ogury has launched its new client-facing platform, Ogury One, designed to revolutionize the way brands and agencies manage their advertising campaigns. As a leader in privacy-centric advertising solutions, Ogury One provides users with a comprehensive suite that facilitates seamless audience planning, activation, and reporting....

Continue Reading
Exploring Top Energy Stocks Benefiting from Industry Shifts

Updated Category News Views 124

Understanding the Shift in Energy Supply Dynamics The global energy landscape is undergoing significant changes, particularly as liquefied natural gas (LNG) supply anticipated an increase. Analysts believe that the next few years will see substantial growth in LNG, especially in response to evolving demand and new technologies. As the market adjusts, smart investors are...

Continue Reading